Literature DB >> 1944918

Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671.

R Voltz1, R Hohlfeld, A Fateh-Moghadam, T N Witt, M Wick, C Reimers, B Siegele, H Wekerle.   

Abstract

Anti-acetylcholine receptor (AChR) antibodies in myasthenia gravis (MG) can be quantitated using AChR extracted from the human rhabdomyosarcoma cell line TE671 (AChRTE671) as a practical alternative to AChR from human amputated limbs (AChRAMP). We compared the two antigen preparations using serum samples from different clinical groups of MG patients (n = 112) and various controls (n = 189). With two exceptions, both tests were positive or negative in the same patients. However, in the generalized MG group, the TE671 assay yielded significantly lower titers than the AChRAMP assay.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1944918     DOI: 10.1212/wnl.41.11.1836

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Antibodies to acetylcholine receptors in patients with different clinical forms of myasthenia and Lambert-Eaton myasthenic syndrome.

Authors:  D V Sidnev; M Yu Karganov; N I Shcherbakova; I B Alchinova; A G Sanadze
Journal:  Neurosci Behav Physiol       Date:  2007-02

Review 2.  Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies.

Authors:  Francesca Andreetta; Elena Rinaldi; Emanuela Bartoccioni; Anna Pia Riviera; Elena Bazzigaluppi; Raffella Fazio; Giovanni Deiana; Alessandro Pini; Maria Grazia Giudizi; Fulvio Baggi
Journal:  Neurol Sci       Date:  2017-10       Impact factor: 3.307

3.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

Authors:  Anna Balandina; Sandrine Lécart; Philippe Dartevelle; Abdelhadi Saoudi; Sonia Berrih-Aknin
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

Review 4.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.